- Torrent Pharma’s first-quarter revenue was 31.78 billion rupees, closely matching the estimated 31.63 billion rupees.
- Domestic sales came in slightly below expectations at 18.11 billion rupees, compared to the estimate of 18.38 billion rupees.
- US revenue outperformed estimates, reaching 3.08 billion rupees against the projected 2.91 billion rupees.
- Brazilian market revenue was slightly below the expected figure, at 2.18 billion rupees compared to an estimate of 2.27 billion rupees.
- Revenue from Germany met the market forecast, recording 3.08 billion rupees against an estimate of 3.1 billion rupees.
- Research and development expenses were lower than anticipated, amounting to 1.57 billion rupees versus the estimated 1.65 billion rupees.
- Analyst recommendations include 19 buys, 10 holds, and 3 sells for Torrent Pharma.
Torrent Pharmaceuticals on Smartkarma
Analysts on Smartkarma, such as Nimish Maheshwari and Tina Banerjee, are bullish on Torrent Pharmaceuticals. Nimish Maheshwari‘s report covers Torrent’s acquisition of JB Chemicals for INR 25,689 crore, marking the second-largest pharma deal in Indian history. This move is set to boost Torrent’s market share, expand its presence in the CDMO sector, and drive revenue growth both domestically and internationally.
Tina Banerjee‘s analysis focuses on Torrent Pharmaceuticals‘ strong Q4FY25 results, showing an 11% YoY increase in net profit and 8% YoY revenue growth driven by the domestic business performance and margin expansion. The company’s performance in the Indian market is particularly highlighted, with revenue growth driven by focus therapies and new launches. With positive trends in the U.S. and Brazil markets, Torrent Pharmaceuticals seems to be on a path towards sustained growth and margin improvement.
A look at Torrent Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Torrent Pharmaceuticals is exhibiting a promising long-term outlook. With high scores in Dividend, Growth, Resilience, and Momentum, the company appears to be well-positioned for success in the pharmaceutical industry. Torrent Pharmaceuticals is known for manufacturing bulk drugs and pharmaceutical formulations, including a range of drugs like cardio-vascular, psychotropic, and anti-biotic medications. Additionally, its presence in various international markets through wholly owned subsidiaries provides further opportunities for growth and expansion.
Investors looking at Torrent Pharmaceuticals may find its overall outlook appealing due to its solid scores in key factors essential for long-term success. The company’s focus on delivering dividends, strong growth potential, resilience, and positive momentum in the market highlight its stability and growth prospects. With a diverse product portfolio and a global presence, Torrent Pharmaceuticals seems to be on a path towards sustained growth and value creation for its stakeholders.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
